To Evaluate the Effect of Nesinaact on Non-alcoholic Steatohepatitis Through MRI and Liver Fibroscan in Patients With Type 2 Diabetes

NCT03950505 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Non-alcoholic Steatohepatitis
Type2 Diabetes

Interventions

DRUG: Nesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) treatment for 24 weeks

Sponsor

Yonsei University